Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bracco Diagnostics, Inc
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
COHORT 1
Is going to receive or has received MULTIHANCE injection during an MRI examination;
Has CKD with eGFR stably comprised between 30 and 59 mL/min/1.73m2, as calculated from a SCr value obtained from the local laboratory within 24 hours prior to the MULTIHANCE injection.
Provides written informed consent and is willing to comply with protocol requirements.
OR
COHORT 2
Is going to receive or has received MULTIHANCE injection during an MRI examination;
Has CKD with eGFR below 30 mL/min/1.73m2, as calculated from a SCr value obtained from the local laboratory within 24 hours prior to the MULTIHANCE injection.
Provides written informed consent and is willing to comply with protocol requirements.
You may not be if
COHORT 1
Has received a GBCA within the past 12 months prior to inclusion in this study;
Has unstable kidney function;
Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives;
Has ever been suspected of, or diagnosed with, NSF prior to the study-specific MRI;
Is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of NSF be suspected.
OR
COHORT 2
Has received a GBCA within the past 12 months prior to inclusion in this study;
Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives;
Has ever been suspected of, or diagnosed with, NSF prior to the study-specific MRI;
Is unable or unwilling to return for necessary office visits, to be examined by dermatologists or to undergo deep skin biopsy should development of NSF be suspected.
